title: Mortality among antiretroviral-eligible patients in an urban public clinic.
abstract: BACKGROUND
  Advances in antiretroviral therapy (ART) over the last decade have improved clinical outcomes for people living with human immunodeficiency virus (HIV), but whether these improvements are experienced by disadvantaged urban populations is less clear.
  
  
  METHODS
  We evaluated mortality among a clinical cohort in a public safety-net HIV specialty clinic in San Francisco, California.
  
  
  RESULTS
  Among 1651 ART-eligible patients attending an urban US HIV clinic, 4-year mortality was 10.0% in 2000-2004 and 11.0% in 2005-2009. Despite universal ART availability, only 72 (42%) of 172 patients who died, compared with 69% of survivors, ever achieved an HIV viral load, 400 copies per cubic millimeter. The leading causes of death were acquired immunodeficiency syndrome (56%), violence/overdose (16%), and pulmonary disease (6%).
  
  
  CONCLUSIONS
  Disadvantaged subpopulations in the developed world can experience high mortality rates despite accessing specialty HIV clinical services with full ART availability. New strategies are needed to improve the outcomes in these populations.
authors: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. david.w.dowdy@gmail.com
authors: David W
authors: DW
authors: Dowdy
authors: Elvin H
authors: EH
authors: Geng
authors: Katerina A
authors: KA
authors: Christopoulos
authors: James S
authors: JS
authors: Kahn
authors: C Bradley
authors: CB
authors: Hare
authors: Daniel
authors: D
authors: Wlodarczyk
authors: Diane V
authors: DV
authors: Havlir
references: Lancet. 2010 Jul 31;376(9738):340-5
references: 20638118
references: PLoS One. 2010 Jun 10;5(6):e11068
references: 20548786
references: Clin Infect Dis. 2010 May 15;50(10):1387-96
references: 20380565
references: J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):342-9
references: 19675463
references: Am J Public Health. 2005 Oct;95(10):1747-52
references: 16186453
references: Ann Intern Med. 2006 Sep 19;145(6):397-406
references: 16983127
references: Int J Epidemiol. 2008 Oct;37(5):948-55
references: 18263650
references: Lancet. 2010 Jul 31;376(9738):367-87
references: 20650518
references: Clin Infect Dis. 2004 Oct 15;39(8):1190-8
references: 15486844
references: Lancet. 2008 Jul 26;372(9635):293-9
references: 18657708
references: Clin Infect Dis. 2006 Jul 15;43(2):234-42
references: 16779752
references: Lancet. 2010 Jul 3;376(9734):49-62
references: 20609987
references: BMJ. 2010 Jul 01;341:c3172
references: 20595255